CR20250060A - ANTI-MONOMETHYL AURISTATIN ANTIBODIES AND ANTIBODY FRAGMENTS. - Google Patents

ANTI-MONOMETHYL AURISTATIN ANTIBODIES AND ANTIBODY FRAGMENTS.

Info

Publication number
CR20250060A
CR20250060A CR20250060A CR20250060A CR20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antibody fragments
adc
payload
monomethyl auristatin
Prior art date
Application number
CR20250060A
Other languages
Spanish (es)
Inventor
M Bordeau Brandon
Ryan Polli Joseph
Duc NGUYEN Toan
P Balthasar Joseph
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of CR20250060A publication Critical patent/CR20250060A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Se proporcionan composiciones y métodos para reducir la toxicidad no objetivo de los conjugados anticuerpo-fármaco (ADC). Las composiciones comprenden un ADC y un agente dirigido al fármaco (carga útil) administrado por el ADC o derivado del mismo. El ADC y el agente dirigido a la carga útil pueden administrarse juntos o por separado en el tratamiento de diversas afecciones (como tumores) mediante ADCs. Ejemplos de agentes dirigidos a la carga útil incluyen anticuerpos, fragmentos o modificaciones de los mismos.Compositions and methods are provided for reducing the off-target toxicity of antibody-drug conjugates (ADCs). The compositions comprise an ADC and a drug-targeting agent (payload) delivered by the ADC or a derivative thereof. The ADC and the payload-targeting agent can be administered together or separately in the treatment of various conditions (such as tumors) by ADCs. Examples of payload-targeting agents include antibodies, fragments, or modifications thereof.

CR20250060A 2022-08-24 2023-08-24 ANTI-MONOMETHYL AURISTATIN ANTIBODIES AND ANTIBODY FRAGMENTS. CR20250060A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263373367P 2022-08-24 2022-08-24
US202363520689P 2023-08-21 2023-08-21
PCT/US2023/072852 WO2024044709A2 (en) 2022-08-24 2023-08-24 Anti-monomethyl auristatin antibodies and antibody fragments

Publications (1)

Publication Number Publication Date
CR20250060A true CR20250060A (en) 2025-03-18

Family

ID=90014109

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250060A CR20250060A (en) 2022-08-24 2023-08-24 ANTI-MONOMETHYL AURISTATIN ANTIBODIES AND ANTIBODY FRAGMENTS.

Country Status (15)

Country Link
EP (1) EP4577568A2 (en)
JP (1) JP2025528390A (en)
KR (1) KR20250060232A (en)
CN (1) CN120035610A (en)
AU (1) AU2023329378A1 (en)
CA (1) CA3265572A1 (en)
CO (1) CO2025002048A2 (en)
CR (1) CR20250060A (en)
DO (1) DOP2025000040A (en)
GE (1) GEAP202516711A (en)
IL (1) IL319054A (en)
JO (1) JOP20250041A1 (en)
MX (1) MX2025002127A (en)
PE (1) PE20251523A1 (en)
WO (1) WO2024044709A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025043019A1 (en) * 2023-08-21 2025-02-27 The Research Foundation For The State University Of New York Slc4a1 (band 3) binding single domain antibodies for increased blood retention
WO2025252100A1 (en) 2024-06-05 2025-12-11 荣昌生物制药(烟台)股份有限公司 Ligand-drug conjugate having free payload recovery unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201425336A (en) * 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
EP3725802A4 (en) * 2017-11-17 2021-08-11 ABL Bio Inc. ANTIBODIES TO ALPHA SYNUCLEIN AND USES THEREOF
CN109912684A (en) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 A kind of Preparation Method And Their Intermediate of the drug-linker MC-MMAF for antibody drug conjugates
WO2021113740A1 (en) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates

Also Published As

Publication number Publication date
GEAP202516711A (en) 2025-06-10
IL319054A (en) 2025-04-01
CO2025002048A2 (en) 2025-07-17
EP4577568A2 (en) 2025-07-02
JOP20250041A1 (en) 2025-02-24
PE20251523A1 (en) 2025-06-05
CA3265572A1 (en) 2024-02-29
KR20250060232A (en) 2025-05-07
WO2024044709A2 (en) 2024-02-29
DOP2025000040A (en) 2025-06-15
AU2023329378A1 (en) 2025-03-06
CN120035610A (en) 2025-05-23
WO2024044709A3 (en) 2024-04-04
MX2025002127A (en) 2025-05-02
JP2025528390A (en) 2025-08-28

Similar Documents

Publication Publication Date Title
CO2025002048A2 (en) Anti-monomethyl auristatin antibodies and antibody fragments
DOP2019000280A (en) STABLE FORMULATIONS OF ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1) AND METHODS FOR THEIR USE
MX2023001163A (en) ANTI-CD79B ANTIBODY DRUG CONJUGATE, METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF.
CO2022007924A2 (en) Anti-mesothelin eribulin antibody drug conjugates and methods of use
DOP2017000177A (en) NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT
MX2023004032A (en) Immuno oncology therapies with il-2 conjugates.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MX2023015471A (en) ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES THAT CHOOSE AS TARGET THE PROTEIN ASSOCIATED WITH THE UROKINASE-TYPE PLASMINOGEN ACTIVATING RECEPTOR (UPARAP).
CL2024002860A1 (en) Antibody-drug conjugates targeting the folate receptor alpha and methods of use
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
MX2022014231A (en) ANTIBODY-DRUG CONJUGATES TARGETING uPARAP.
CL2025002617A1 (en) Antibody-drug conjugates administered subcutaneously for use in the treatment of cancer
CL2025001214A1 (en) Anti-CD7 antibody-drug conjugates and methods of using them
MX2025007523A (en) Antibody-drug conjugates targeting uparap comprising exatecan derivatives
CL2023003905A1 (en) Novel conjugates comprising phosphoantigens and their therapeutic use
CO2021016982A2 (en) Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of bile duct cancers
DOP2025000322A (en) NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
AR130809A1 (en) ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE
AR134425A1 (en) ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
CO2025006752A2 (en) Anti-CD7 antibody-drug conjugates and methods of using them
PY24103486A (en) ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
CO2025008795A2 (en) TLR7 agonists and antibody-drug conjugates thereof
WO2025078881A3 (en) Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof
CO2025002304A2 (en) Combination therapies for cancer treatment